Table 3.
aHRs by Glucose-Lowering Regimen
| Parameter | Primary End Point |
All-Cause Mortality |
MACE |
Cancer |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aHR | 95% CI | P Value | aHR | 95% CI | P Value | aHR | 95% CI | P Value | aHR | 95% CI | P Value | |||||
| Metformin monotherapy (referent) | 1.000 | 1.000 | 1.000 | 1.000 | ||||||||||||
| Sulfonylurea monotherapy | 1.436 | 1.354 | 1.523 | <.0001 | 1.749 | 1.643 | 1.863 | <.0001 | 1.392 | 1.251 | 1.549 | <.0001 | 1.097 | 1.004 | 1.199 | .0410 |
| Metformin + sulfonylurea | 1.024 | 0.963 | 1.090 | .4454 | 1.100 | 1.022 | 1.184 | .0111 | 1.095 | 0.982 | 1.221 | .1035 | 0.956 | 0.877 | 1.043 | .3120 |
| Insulin monotherapy | 1.808 | 1.630 | 2.005 | <.0001 | 2.197 | 1.983 | 2.434 | <.0001 | 1.736 | 1.441 | 2.092 | <.0001 | 1.437 | 1.234 | 1.674 | <.0001 |
| Insulin + metformin | 1.309 | 1.150 | 1.491 | <.0001 | 1.344 | 1.148 | 1.575 | .0002 | 1.217 | 0.963 | 1.539 | .1001 | 1.394 | 1.176 | 1.651 | .0001 |
| Eye Complications | Neuropathy | Renal Complications | Combined Microvascular | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metformin monotherapy (referent) | 1.000 | 1.000 | 1.000 | 1.000 | ||||||||||||
| Sulfonylurea monotherapy | 1.026 | 0.960 | 1.097 | .4514 | 1.127 | 1.011 | 1.256 | .0303 | 2.632 | 2.198 | 3.151 | <.0001 | 1.097 | 1.033 | 1.165 | .0024 |
| Metformin + sulfonylurea | 1.208 | 1.143 | 1.278 | <.0001 | 1.214 | 1.102 | 1.337 | .0001 | 1.389 | 1.122 | 1.720 | .0026 | 1.214 | 1.153 | 1.279 | <.0001 |
| Insulin monotherapy | 1.171 | 1.057 | 1.298 | .0026 | 2.146 | 1.832 | 2.514 | <.0001 | 3.504 | 2.718 | 4.518 | <.0001 | 1.363 | 1.240 | 1.498 | <.0001 |
| Insulin + metformin | 1.181 | 1.055 | 1.321 | .0037 | 2.318 | 1.964 | 2.736 | <.0001 | 1.667 | 1.091 | 2.547 | .0182 | 1.326 | 1.196 | 1.470 | <.0001 |